Having trouble viewing? View as Webpage
MPNRF ADVANCING RESEARCH
Preventing Blood Clots in MPNs
Blood clots, heart attacks, and strokes are leading causes of death or disability in patients with MPNs, typically as a result of elevated platelets and/or red blood cells. Dr. Joan Beckman’s lab at University of Minnesota is currently working to determine whether growth-arrest-specific 6 protein (Gas6) contributes to blood clots in these individuals. The work is funded by a 2022 MPNRF Thrive award.  

The Gas6 pathway is known to promote blood clot formation. However, it is not known if this pathway contributes to blood clots in MPNs. 
 
“My lab works to find ways to stop blood clots and prevent (associated) damage,” according to Dr. Beckman.
Joan Beckman, MD, PhD
RESEARCH NOTES
Today’s Understanding of MPNs: Review Articles in ASH Journal Blood 
Last month, in the American Society of Hematology (ASH) journal Blood, a review series featured key articles about MPNs (Vol 141 Number 16: April 20, 2023). The articles, some of which include work partly funded by MPNRF, describe the latest advances in the world’s understanding of MPNs. 
AACR Annual Meeting MPN Highlights
While April’s Annual Meeting of the American Association for Cancer Research (AACR) focused a great deal on understanding, decoding, and advocating for cancer health equity and inclusion, there were also significant scientific take-aways important to the treatment of MPNs. 
FOUNDER'S DAY
We may have met our goal, but you still have time to help us BEAT it!
MPN research supporters like you have helped MPNRF reach our base goal of $60K (including a generous gift from the family of our founder, Robert Rosen). Thank you!

If you haven’t made a gift yet in honor of Founder’s Day, there is still time to be part of this fundraising event. Help us reach our new goal of $75K before the month's end to unlock additional MPN research investment! 
RESOURCES TO SHARE
New Resource for Living with MF
insidemyMF.com is a new website by CTI BioPharma where patients, loved ones, and other care partners can find unique perspectives on myelofibrosis, compelling patient stories, and resources to help build an expanded understanding of living with myelofibrosis.
Clinical Trial Finder
As MPN research continues to rapidly advance, participating in a clinical trial can offer the opportunity to access new treatments for ET, PV, and MF. It is also an important part of the drug development process necessary to bring new approved treatments to more people living with an MPN.  
 
Learn more about how MPNRF's personalized clinical trial finder matches an MPN patient’s diagnosis and treatment history with currently enrolling clinical studies that may be available to them. Learn more >>
ATTN: MPN Clinicians and Care Team Members
The National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Clinicians have been updated to include BESREMi (ropeginterferon alfa-2b njft) as a preferred therapeutic option for the treatment of adults with both high and low-risk polycythemia vera (PV), regardless of treatment history. Additional important updates for MPN patients are included in the May update. Click below to learn more.
Clinical Trial Highlights
Company: PharmaEssentia 
 
This is a study of ropeginterferon alfa-2b-njft (marketed as BESREMi®) which was approved by the FDA for use in PV in 2021. The trial will evaluate whether more rapid hematologic and molecular response, indicating potential disease modifying activity and long-term disease control, is achieved utilizing accelerated dosing in PV patients.
Sponsor: University of Washington 

Patients with accelerated or blast phase MPNs prior to hematopoietic stem cell transplant are treated in this study with decitabine plus ruxolitinib or fedratinib for up to six cycles of 28 days. Participants in this investigator-initiated study would need to travel to the trial site in Seattle, WA.
GSK logo
Our mission is supported by the generosity of our donors and sponsors.
180 N. Michigan Avenue, Suite 1870 | Chicago, IL 60601